| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2081278 | Drug Discovery Today | 2014 | 4 Pages |
Abstract
•‘Big data’ provide challenges and opportunities for pharmaceutical R&D.•Currently available compound activity data and target annotations have ‘big data’ character.•Achieving compound data completeness is an elusive goal.•Extraction of knowledge from ‘big compound data’ is a must and does not depend on data completeness.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Ye Hu, Jürgen Bajorath,